(CercleFinance.com) – Eurobio Scientific, a specialist in the detection of infectious diseases, announced on Monday that it was going to join forces with NextStage AM, which will invest 35.5 million euros in a holding company called EurobioNext.
Under the terms of the transaction, EurobioNext would hold some 3.2 million ordinary shares of Eurobio Scientific, or the equivalent of approximately 28.3% of the capital.
The majority of EurobioNext’s capital would be held by Eurobio’s two reference executive shareholders, Jean-Michel Carle Grandmougin and Denis Fortier, with approximately 56.5%.
NextStage and FPCI Pépites et Territoires, a subsidiary of AXA, will hold 43.5%.
The operation, which should allow Eurobio Scientific to accelerate its development, is based on a unit price per Eurobio Scientific share of 25.28 euros.
At around 22.6 euros, the stock price of the specialist in in vitro medical diagnostics and life sciences did not yet adjust to this price on Monday morning, but still posted a gain of more than 5%.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information about EUROBIO SCIENTIFIC in real time: